RAB32 mutation in Parkinson's disease
- PMID: 39304252
- DOI: 10.1016/S1474-4422(24)00324-7
RAB32 mutation in Parkinson's disease
Erratum in
-
Correction to Lancet Neurol 2024; 23: 961-62.Lancet Neurol. 2024 Dec;23(12):e15. doi: 10.1016/S1474-4422(24)00452-6. Lancet Neurol. 2024. PMID: 39577926 No abstract available.
Conflict of interest statement
ADF received fees for advisory board participation from Bial; consulting fees from Bial, Sanofi Genzyme, and Zambon; and support for attending meetings from Sanofi. All other authors declare no competing interests. This study was partially funded by the Italian Ministry of Health (current research IRCCS—ParkNet project) and grants from the Fresco Parkinson Institute. The research centre CMP3 VdA and the Project 5000genomi@ VdA are co-funded by Fondo Europeo di Sviluppo Regionale (FESR) Programma Investimenti per la crescita e l’occupazione 2014/20 (European Social Fund [ESF] and European Regional Development Fund), the Autonomous Region of the Aosta Valley, and the Italian Ministry of Labour and Social Policy (CUPB68H19005520007). This work was also supported by a grant from the EU-ESF, the Autonomous Region of the Aosta Valley, and the Italian Ministry of Labour and Social Policy. See the appendix for a list of ParkNet Study Group members involved in this project (p 5) and a complete list of ParkNet Study Group members (p 6).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical